{"disease":{"id":"egfr-t790m","name":"egfr t790m"},"drugs":{"marketed":[{"drug_id":"osimertinib","indication_name":"Treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tagrisso","generic_name":"osimertinib","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"ALK tyrosine kinase receptor","drug_class":"Kinase Inhibitor [EPC]","quality_score":67,"revenue":"5800","mechanism":"Osimertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that binds irreversibly to mutant forms of EGFR."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05377788","title":"Lazertinib Real-world Observational Study of in Pre-treated EGFR T790M Mutant With Advanced Non-small Cell Lung Cancer","phase":"","overall_status":"UNKNOWN","enrollment_count":900,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT06573073","title":"Evaluation of Clinical Performance and IVD Test of LifeOS Digital PCR Liquid Biopsy Kits for EGFR T790M Mutation","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"LifeOS Genomics Corporation","has_results":false},{"nct_id":"NCT03861156","title":"D-0316 in Patients With EGFR Positive Non Small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":290,"lead_sponsor_name":"InventisBio Co., Ltd","has_results":false},{"nct_id":"NCT04592666","title":"Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":226,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04862780","title":"(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":177,"lead_sponsor_name":"Blueprint Medicines Corporation","has_results":false},{"nct_id":"NCT05701384","title":"Lazertinib 160mg in EGFR T790M NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":117,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT03543683","title":"Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":115,"lead_sponsor_name":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","has_results":false},{"nct_id":"NCT03532698","title":"Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","has_results":false},{"nct_id":"NCT04116918","title":"Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Baodong Qin","has_results":false},{"nct_id":"NCT05458726","title":"Correlation Between Efficacy of Osimertinib and EGFR T790M Status and Ratio Via ddPCR in NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Peking Union Medical College","has_results":false},{"nct_id":"NCT03257124","title":"Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":80,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT02454933","title":"Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT03810066","title":"Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"University Hospital, Essen","has_results":false},{"nct_id":"NCT02451852","title":"AZD9291 US Expanded Access Program","phase":"","overall_status":"NO_LONGER_AVAILABLE","enrollment_count":null,"lead_sponsor_name":"AstraZeneca","has_results":false}],"total":14},"guidelines":[],"source":"Drug Landscape verified database"}